{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:49:40Z","timestamp":1792014580901,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ctrv.2026.103215","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:17:17Z","timestamp":1790180237000},"page":"103215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reduced oxaliplatin exposure in gastrointestinal cancers: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"150","author":[{"given":"Wallace Klein","family":"Schwengber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fares","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Felipe Leite","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Segovia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alsulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayla","family":"Kouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluseyi","family":"Abidoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Benkhadra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6931-242X","authenticated-orcid":false,"given":"Mohamad Bassam","family":"Sonbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103215_bb0005","series-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) colon cancer","author":"Benson","year":"2025"},{"key":"10.1016\/j.ctrv.2026.103215_bb0010","series-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) gastric cancer","author":"Ajani","year":"2026"},{"key":"10.1016\/j.ctrv.2026.103215_bb0015","series-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) pancreatic adenocarcinoma","author":"Tempero","year":"2025"},{"issue":"30","key":"10.1016\/j.ctrv.2026.103215_bb0020","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2014.58.8533","article-title":"Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (alliance)","volume":"33","author":"Pachman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103215_bb0025","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","article-title":"Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials","volume":"21","author":"Andr\u00e9","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103215_bb0030","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1200\/JCO.21.02726","article-title":"Prognostic impact of early treatment and oxaliplatin discontinuation in patients with stage III colon cancer: an ACCENT\/IDEA pooled analysis of 11 adjuvant trials","volume":"41","author":"Gallois","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103215_bb0035","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mdy064","article-title":"The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?","volume":"29","author":"Sobrero","year":"2018","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103215_bb0040","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1200\/JCO.19.00281","article-title":"Duration of oxaliplatin-containing adjuvant therapy for stage III colon cancer: ASCO clinical practice guideline","volume":"37","author":"Lieu","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103215_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.4489","article-title":"The role of maintenance strategies in metastatic colorectal cancer: a systematic review and network meta-analysis of randomized clinical trials: a systematic review and network meta-analysis of randomized clinical trials","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103215_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101572","article-title":"S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial","volume":"8","author":"Stocker","year":"2023","journal-title":"ESMO Open"},{"issue":"29","key":"10.1016\/j.ctrv.2026.103215_bb0055","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1200\/JCO.20.03329","article-title":"Randomized phase II trial evaluating two sequential treatments in first line of metastatic pancreatic cancer: results of the PANOPTIMOX-PRODIGE 35 trial","volume":"39","author":"Dahan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103215_bb0060","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab043","article-title":"The early impact of the IDEA collaboration results: how the results changed prescribing practice","volume":"5","author":"Iveson","year":"2021","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103215_bb0065","first-page":"79","article-title":"Impact of the IDEA collaboration study results on clinical practice in France for patients with stage III colon cancer: a national GERCOR - PRODIGE survey","volume":"20","author":"Ouali","year":"2021","journal-title":"Clin Colorectal Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103215_bb0070","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ijc.34149","article-title":"Translation of IDEA trial results into clinical practice: analysis of the implementation of a new guideline for colon cancer","volume":"151","author":"van Rooijen","year":"2022","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103215_bb0075","doi-asserted-by":"crossref","first-page":"841","DOI":"10.6004\/jnccn.2023.7028","article-title":"Changes in prescribing patterns in stage III colon cancer","volume":"21","author":"Ou","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2026.103215_bb0080","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2026.103215_bb0085","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.ctrv.2026.103215_bb0090","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2026.103215_bb0095","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103215_bb0100","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO-25-00621","article-title":"Three versus 6 months of adjuvant oxaliplatin-fluoropyrimidine chemotherapy for colorectal cancer: final results of SCOT-an international, randomized, phase III, noninferiority trial","volume":"44","author":"Iveson","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103215_bb0105","article-title":"Comparison of the efficacy of S-1 plus oxaliplatin or Capecitabine plus oxaliplatin for six and eight chemotherapy cycles as adjuvant chemotherapy in patients with stage II-III gastric cancer after D2 resection","volume":"11","author":"Yu","year":"2021","journal-title":"Front Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2026.103215_bb0110","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1200\/JCO.2017.76.0355","article-title":"Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, international duration evaluation of adjuvant (IDEA) France, phase III trial","volume":"36","author":"Andr\u00e9","year":"2018","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.ctrv.2026.103215_bb0115","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.21.02628","article-title":"Final analysis of 3 versus 6 months of adjuvant oxaliplatin and fluoropyrimidine-based therapy in patients with stage III colon cancer: the randomized phase III ACHIEVE trial","volume":"40","author":"Yoshino","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103215_bb0120","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/annonc\/mdz193","volume":"30","author":"Souglakos","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103215_bb0125","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.annonc.2020.10.477","article-title":"Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial","volume":"32","author":"Petrelli","year":"2021","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2026.103215_bb0130","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/jama.2021.2454","article-title":"Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer: the CALGB\/SWOG 80702 (Alliance) randomized clinical trial: the CALGB\/SWOG 80702 (alliance) randomized clinical trial","volume":"325","author":"Meyerhardt","year":"2021","journal-title":"JAMA"},{"issue":"33","key":"10.1016\/j.ctrv.2026.103215_bb0135","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1200\/JCO.21.02962","article-title":"Oxaliplatin (3 months v 6 months) with 6 months of Fluoropyrimidine as adjuvant therapy in patients with stage II\/III Colon Cancer: KCSG CO09-07","volume":"40","author":"Kim","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103215_bb0140","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","article-title":"OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer--a GERCOR study","volume":"24","author":"Tournigand","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103215_bb0145","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/bjc.2017.93","article-title":"Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study","volume":"116","author":"Guren","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103215_bb0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1634\/theoncologist.2011-0249","article-title":"First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study","volume":"17","author":"D\u00edaz-Rubio","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103215_bb0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejca.2018.06.024","article-title":"First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: phase II randomised MACRO2 TTD study","volume":"101","author":"Aranda","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103215_bb0160","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2019.07.006","article-title":"SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer","volume":"119","author":"Munemoto","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103215_bb0165","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejca.2017.06.008","article-title":"A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer","volume":"83","author":"Park","year":"2017","journal-title":"Eur J Cancer"},{"issue":"114207","key":"10.1016\/j.ctrv.2026.103215_bb0170","article-title":"Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months","volume":"208","author":"Franken","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103215_bb0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12029-024-01135-2","article-title":"Adjuvant chemotherapy duration and disease-free survival in low-risk stage III colon cancer with N1a-b and N1c disease: insights from a single-center retrospective analysis","volume":"56","author":"Karao\u011flan","year":"2024","journal-title":"J Gastrointest Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103215_bb0180","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4103\/njcp.njcp_848_23","article-title":"Assessing the efficacy and safety of shorter versus extended adjuvant treatment duration for stage III low-risk colon cancer: a comparative analysis","volume":"28","author":"Kalkan","year":"2025","journal-title":"Niger J Clin Pract"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103215_bb0185","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s12029-015-9746-8","article-title":"Impact of dose reductions, delays between chemotherapy cycles, and\/or shorter courses of adjuvant chemotherapy in stage II and III colorectal cancer patients: a single-center retrospective study","volume":"46","author":"Sgouros","year":"2015","journal-title":"J Gastrointest Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103215_bb0190","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1159\/000531722","article-title":"Comparison of the efficacy and safety of 3 months of CAPOX followed by 3 months of capecitabine and 6 months of CAPOX\/FOLFOX in the adjuvant treatment of low-risk stage III colon cancer treated surgically","volume":"101","author":"Bardakci","year":"2023","journal-title":"Oncology"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103215_bb0195","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.3390\/curroncol30070478","article-title":"The association of oxaliplatin-containing adjuvant chemotherapy duration with overall and cancer-specific mortality in individuals with stage III colon cancer: a population-based retrospective cohort study","volume":"30","author":"Sue-Chue-Lam","year":"2023","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103215_bb0200","first-page":"262","article-title":"Effect of adjuvant FOLFOX chemotherapy duration on outcomes of patients with stage III colon cancer","volume":"14","author":"Kumar","year":"2015","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ctrv.2026.103215_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.641044","article-title":"Maintenance therapy in first-line gastric and gastroesophageal junction adenocarcinoma: a retrospective analysis","volume":"11","author":"Walden","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2026.103215_bb0210","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2020.07.031","article-title":"A new prognostic and predictive tool for shared decision making in stage III colon cancer","volume":"138","author":"Sobrero","year":"2020","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103215_bb0215","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:34Z","timestamp":1792012354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":43,"alternative-id":["S0305737226001295"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103215","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced oxaliplatin exposure in gastrointestinal cancers: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103215"}}